Moreover, RNA interference-mediated downregulation of Cav-1 mitigates α-synuclein-induced cell death, indicating that Cav-1 may serve as a promising therapeutic target to reduce α-synuclein toxicity in PD [237]. This evidence concerns the gene SNCA and Parkinson disease.